Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Terran Biosciences.

    Client Virtual Booth

    TERRAN BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Terran Biosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Hudson Yards New York, NY
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://terranbiosciences.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/terran/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Development Milestones

    Details:

    Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.


    Lead Product(s): Idazoxan

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Pierre Fabre

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement June 02, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-MeO-DMT And Long-Acting MDMA

    Details:

    N,N-dimethyltryptamine is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.


    Lead Product(s): Dimethyltryptamine

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets

    Details:

    Terran plans to quickly advance the development of the lead SAR442168 and other assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need.


    Lead Product(s): Tolebrutinib

    Therapeutic Area: Neurology Product Name: SAR442168

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Sanofi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 21, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreaking Discoveries of Prominent Psychedelics ...

    Details:

    Blumentech's patents further complement Terran's rapidly growing IP portfolio of over 150 patent applications in the psychedelic space, which includes patents on Terran's orally-active DMT compound, a product of Terran's robust medicinal chemistry drug discovery program.


    Lead Product(s): Dimethyltryptamine

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Blumentech S.L.

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 13, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search